



NASDAQ: VTVT

Improving the Lives of  
Millions of Patients  
with Type 1 Diabetes

---

---

THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. FORWARD-LOOKING STATEMENTS INCLUDE ALL STATEMENTS THAT ARE NOT HISTORICAL FACTS AND CAN BE IDENTIFIED BY TERMS SUCH AS "ANTICIPATES," "BELIEVES," "COULD," "SEEKS," "ESTIMATES," "EXPECTS," "INTENDS," "MAY," "PLANS," "POTENTIAL," "PREDICTS," "PROJECTS," "SHOULD," "WILL," "WOULD" OR SIMILAR EXPRESSIONS AND THE NEGATIVES OF THOSE TERMS.


THESE FORWARD-LOOKING STATEMENTS ARE ONLY ESTIMATES BASED UPON THE INFORMATION AVAILABLE TO VTV THERAPEUTICS INC. (OR THE PARTY PREPARING SUCH FORWARD-LOOKING STATEMENTS) AS OF THE DATE OF THIS PRESENTATION. THE FORWARD-LOOKING STATEMENTS INCLUDED HEREIN INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES AND OTHER IMPORTANT FACTORS SUCH THAT ACTUAL FUTURE OPERATIONS, OPPORTUNITIES, PRODUCT DEVELOPMENT PROCESSES AND OUTCOMES, CLINICAL TRIAL PROCESSES AND OUTCOMES, REGULATORY APPROVAL PROCESSES AND OUTCOMES, ECONOMIC PERFORMANCE OF PRODUCTS, FUND-RAISING ACTIVITIES AND FINANCIAL PERFORMANCE MAY DIFFER MATERIALLY FROM THOSE SET FORTH IN OR IMPLIED IN THESE FORWARD-LOOKING STATEMENTS. THESE RISKS, UNCERTAINTIES, AND OTHER FACTORS, WHICH MAY NOT BE WITHIN OUR CONTROL, ARE DISCUSSED IN MORE DETAIL IN OUR QUARTERLY, ANNUAL AND CURRENT REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING, WITHOUT LIMITATION, UNDER THE CAPTIONS, "RISK FACTORS," "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS" AND "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." THEREFORE, YOU SHOULD READ THIS PRESENTATION IN CONJUNCTION WITH SUCH MEANINGFUL CAUTIONARY STATEMENTS.

UNDUE RELIANCE SHOULD NOT BE PLACED ON FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF. EXCEPT AS REQUIRED BY LAW, WE EXPRESSLY DISCLAIM ANY RESPONSIBILITY TO PUBLICLY UPDATE OR REVISE OUR FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE. ALL FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE QUALIFIED IN THEIR ENTIRETY BY THE FOREGOING CAUTIONARY STATEMENTS.

THIS PRESENTATION IS BEING PROVIDED TO YOU FOR INFORMATION PURPOSES ONLY. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SALE OF (OR THE SOLICITATION OF AN OFFER TO BUY) ANY SECURITIES OF VTV THERAPEUTICS INC. OR ANY OF ITS SUBSIDIARIES.

BY ACCEPTING THIS PRESENTATION, YOU ACKNOWLEDGE AND AGREE THAT (I) YOU WILL NOT RELY ON THIS PRESENTATION FOR MAKING ANY INVESTMENT DECISION WITH RESPECT TO ANY SECURITIES OF VTV THERAPEUTICS INC. OR ANY OF ITS SUBSIDIARIES, AND (II) ANY INVESTMENT DECISION MADE BY YOU WITH RESPECT TO ANY SUCH SECURITIES WILL BE BASED SOLELY ON AN OFFERING DOCUMENT RELATING TO SUCH SECURITIES (IF ANY), INCLUDING THE INFORMATION INCORPORATED BY REFERENCE THEREIN.

# New Leadership Builds upon Decades of Scientific & Clinical Expertise



<p><b>Paul Sekhri</b> President &amp; CEO</p>	<p><b>Jon Isaacsohn, MD</b> Chairman</p>	<p><b>Carmen Valcarce, PhD</b> Chief Scientific Officer</p>	<p><b>Thomas Strack, MD</b> Chief Medical Officer</p>	<p><b>Steven Tuch</b> CFO</p>	<p><b>Rich Nelson</b> Head of CorpDev</p>	<p><b>Martin Lafontaine</b> Commercial Consultant</p>



## Distinguished SAB Continues to Support Development of Cadisegliatin (TTP399)



**John Buse, MD, PhD**  
Verne S. Caviness Distinguished Professor  
Director, Diabetes Center  
Director, NC Translational & Clinical Sciences Institute



**G. Alexander "Zan" Fleming, MD**  
Founder & Executive Chairman, Kinexum  
Former FDA Supervisory Physician for Diabetes



**Justin Gregory, MD, MSc**  
Asst. Professor of Pediatrics  
Pediatric Endocrinology



**Gary Koch, PhD**  
Professor, Department of Biostatistics  
Director, Biometric Consulting Laboratory



**Robert Rizza, MD**  
Emeritus Professor of Medicine  
Division of Endocrinology, Diabetes,  
Metabolism & Nutrition




**Jay Skyler, MD, MACP, FRCP**  
Professor of Medicine, Pediatrics, & Psychology  
Division of Endocrinology, Diabetes, & Metabolism  
Deputy Director for Clinical Research & Academic  
Programs, Diabetes Research Institute




---

## Living with T1D is Like Driving Too Fast on a Dangerous Road

~80% of patients fail to achieve adequate blood glucose control. Fear of hypoglycemia is so intense that many accept high blood glucose, risking long-term health consequences and diabetic ketoacidosis (DKA).



## Hypoglycemia: The Plague of T1D



1. Cryer PE. The barrier of hypoglycemia in diabetes. *Diabetes*. 2008;57(12):3169-76.


2. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. *Diabetes Technol Ther*. 2019.

3. dQ&A Market Research 2019.

4. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabet Med*. 2012 May;29(5):682-9. doi: 10.1111/j.1464-5491.2012.03605.x. PMID: 22313123; PMCID: PMC3433794

## Cadiseigliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3

Glucokinase is present in both pancreatic  $\beta$ -cells & the liver.  
Past efforts to target have failed due to an increase in hypoglycemic events among other issues\*



\*Other factors: Loss of potency over time; hypertriglyceridemia; fatty liver. None of these have been observed with cadiseigliatin preclinically or in clinical studies up to 6 months.

---

## **Cadisegliatin:**


A First In Class Adjunctive Therapy to Insulin for the Treatment of Type 1 Diabetes

A Liver-Selective Glucokinase Activator that:


- 1) Reduces the Risk of Hypoglycemia**
- 2) Improves Glycemic Control**




## In Healthy Patients, the Liver Acts as a Reservoir for Glucose





## With Type 1 Diabetes, Glucokinase Activity in the Liver is Impaired



## Cadisegliatin Reactivates Innate Glucose-Regulating Capacity of the Liver




## Our SimpliciT1 Trial Demonstrated Statistically & Clinically Significant Efficacy & Confirmed Safety



Randomized, Double-Blind, Placebo Controlled 2-Part Study of ~100 patients. A total of 46 patients in the treatment groups received 800mg daily of cadisegliatin.

Study Details: <https://diabetesjournals.org/care/article/44/4/960/138590/The-SimpliciT1-Study-A-Randomized-Double-Blind> & <https://clinicaltrials.gov/ct2/show/NCT03335371>

Cadiseigliatin MoA of reducing hyperglycemic stress could be complementary to other interventions in T1D, in addition to preventing the long-term sequelae of both hyper- and hypoglycemia



---

## High Level Commercial Opportunity Assessment

**\$1.7B - \$2.8B**

Peak U.S. Sales Opportunity

***Further Upside:***

Ex-US Markets;

T2D indication adds ~2.8M lives

- ◆ **Base Case** Cadisegliatin Product Profile  
(≥ 30% reduction hypoglycemic episodes; Δ HbA1c ≥ -0.5%)
- ◆ **1.6M** people, **growing 2.9%** annually <sup>1</sup>
- ◆ **\$600 Monthly** WAC <sup>2</sup>
- ◆ **2028** Product Launch <sup>3</sup>
- ◆ **15% - 25%** peak population uptake <sup>3</sup>
- ◆ **70%** adherence rate <sup>3</sup>

<sup>1</sup> Type 1 Diabetes Index website. Available at [t1diindex.org](https://t1diindex.org). Accessed on September 28th, 2023.

<sup>2</sup> Prescription Drug Disclosure program. Texas HHS. Available at <https://www.dshs.texas.gov/prescription-drug-price-disclosure-program>

<sup>3</sup> Internal, vTv Therapeutics



## Pipeline Creates Additional Upside

vTv Partner vTv + Partner

PRODUCT	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	PARTNERS + REGIONS
<b>Cadiseigliatin (TTP399)</b> GK Activator					 Certain countries in the Middle East, Africa, and Central Asia
<b>TTP273</b> Oral GLP-1R Agonist					 Asia (excl. Japan)
<b>HPP737</b> PDE4 Inhibitor					 Asia (excl. Japan)
<b>Mavodelpar (HPP593)</b> PPAR- $\delta$ Agonist					 Worldwide
<b>Azeliragon</b> RAGE Antagonist					 Worldwide
<b>HPP3033</b> Nrf2/Bach1 Modulator					
<b>TTP-RA</b> RAGE Antagonist					

---

We Have the Opportunity to Ease the Burden of Managing T1D and Improve the Lives of Patients Living with Type 1 Diabetes





---

## Conclusions



Cadiseqliatin significantly improved glycemic control



Cadiseqliatin had a favorable safety profile: reduction of hypoglycemia and ketosis events



**FDA has granted cadiseqliatin Breakthrough Designation for the Treatment of T1D**



Poised to initiate phase 3 trials for cadiseqliatin